CA2094773C - 2,4-dioxoimidazolidine derivatives - Google Patents
2,4-dioxoimidazolidine derivatives Download PDFInfo
- Publication number
- CA2094773C CA2094773C CA002094773A CA2094773A CA2094773C CA 2094773 C CA2094773 C CA 2094773C CA 002094773 A CA002094773 A CA 002094773A CA 2094773 A CA2094773 A CA 2094773A CA 2094773 C CA2094773 C CA 2094773C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- denotes
- aryl
- compound
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Abstract
The present invention relates to 2,4-dioxoimidazolidine derivatives of the general formula I
(see figure I) wherein R1 is, fox example,-(CH2)n-NH-X, where n is an integer from 1 to 6 and X is, for example, hydrogen or (C1-C6)-alkyl, R2 is hydrogen or (C1-C6)-alkyl, R3 is hydrogen or phenyl, R4 is, for example, COOR5, where R5 is (C1-C28)-alkyl and Y is, for example, -(CH2)m-CO- radical where m represents an integer from 1 to 4. The compounds of the invention are useful as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
(see figure I) wherein R1 is, fox example,-(CH2)n-NH-X, where n is an integer from 1 to 6 and X is, for example, hydrogen or (C1-C6)-alkyl, R2 is hydrogen or (C1-C6)-alkyl, R3 is hydrogen or phenyl, R4 is, for example, COOR5, where R5 is (C1-C28)-alkyl and Y is, for example, -(CH2)m-CO- radical where m represents an integer from 1 to 4. The compounds of the invention are useful as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
Description
l-:i- :fl! .!
_ ' CA 02094773 2002-11-22 ~-~~,"g~zolidine~ derivat:~,vgrs The present invention relates to 2,4-dioaoimidazolidine derivatives, their preparation aad their nse as inhibitors of blood platelet aggregation.
Hydaatoin derivatives having thraa~bocyte aggregation-inhibiting action are described in EP-A 449,079, aad in the uapublished Germaa Patent Application p 41 2s 2'7.8.
published on February 13, 2002, publication number DE-A 41 26 277. Further research has shown that the compounds of the present invention are also gotent inhibitors of blood platelet aggregation.
The present invention relates to compounds of the general formula I.
caaH
H I
R 1-.C~ I H 2 4 H-lf-N H'-C"tt R 2-i~l~ I 3 a R
In whlCh Y deaotes -(CHs):-C~-, where m represeats as integer from 1 to 4, or n v ~ , Rl denotes - ( CHZ ) n NH-X, where n represents an integer from I t0 6, - ( CHZ ) p-C6H,-NH-X, - ( CHZ ) p-CaH,-C (=NH ) 'NHZ Or - ( CHZ ) p-C6H~-C&~-NB-X, where p in each case represents 1 or 2 , but also where instead of C H-~R 1 C'~C H~C 6114-x 1 can be present;
%1 deaotes -NBX, -CHI or -C(=HH)-HH=i 8 deaotes hydrogen, (Ci C6)-alkyl or a radical of the formula II
r Ref.3507 ne0045 2G9~~'~'~3 R' -NH-C~1-R "
where R' and R " independently of one another represent hydrogen or (C1-Cs)-alkyl;
R2 denotes hydrogen or (Cl-Cs)-alkyl;
R3 denotes hydrogen or phenyl;
R' denotes -COORS, CO-N ( C83 ) -RS or -CO-NH-R5;
Rs denotes (C1-C2g)-alkyl which is substituted a) by mono- or di-(C1-Cls)-alkylaminocarbonyl, amino-( CZ Cl' ) -alkylaminocarbonyl, amino- ( Ci C3 ) -alkylphenyl-(Cl-C3)-alkylaminocarbonyl, (C1-Cls)-alkylcarbonylamino-(Ci-C3)-alkylphenyl-(C1-C3)-alkylaminocarbonyl or (Ci-Cle)-alkylcarbonylamino-(C2-C1')-alkylaminocarbonyl, where the alkyl radicals for their part can be substituted by hydroxyl, amino, mercapto, (C1-Cis)-alkoxy, halogen, vitro, trifluoromethyl, ( Cs-C1' ) -aryl or ( Cs-C1' ) -aryl- ( C1-Ca ) -alkyl and which b) is optionally additionally monosubatituted or polysubstituted by identical or different radicals from the series consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, amino, mercapto, ( C1-Cls ) -alkoxy, ( C1-Cls ) -alkoxycarbonyl, ( Cs-C1' ) -aryl-(Cl-C3)-alkoxycarbonyl, (C3-Cs)-cycloalkyl, halogen, vitro, trifluoromethyl and a radical Rs;
Rs denotes ( Cs-C1' ) -aryl, ( Cs-Cl' ) -aryl- ( C1-Cs ) -alkyl , a monocyclic or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which, as the heteroelement, can contain one, two or three identical or different nitrogen, oxygen or sulphur atoms, or denotes a radical R~, where the aryl radical and, independently thereof, the heterocyclic radical can be optionally monoaubstituted or polyaubstituted by identical or different radicals from the series consisting of (C1-ClBj-alkyl, (C1-Cls)-alkoxy, halogen, vitro and trifluoromethyl;
R' denotes -NRBRs, -ORs, -SRs, an amino acid side chain, a natural or unnatural amino acid residue, imino acid residue, optionally N- ( C1-Ce ) -alkylated or ( Cs-C1, ) -aryl- ( C1-Ce ) -alkylated azaamino acid residue or dipeptide residue, in which the peptide Ref.3507 ' ne0045 bond can be~reduced to NH-CH2, and also their esters and amides, where free functional groups can optionally be substituted by hydrogen or hydroxymethyl or be protected by protective groups customary in peptide chemistry, or denotes a radical -COR'', in which R'~ is defined as R';
Re denotes hydrogen, ( C2-C18 ) -alkyl, ( CB-C1, ) -aryl-(C1-Ce)-alkyl, (Cl-Cle)-alkylcarbonyl, (Cl-C18)-alkoxycarbonyl, ( Cs-C1, ) -arylcarbonyl, ( Cs-C1, ) -aryl- ( C1-Ce ) -alkylcarbonyl, or (CB-Cl,)-aryl-(C1-C18)-alkoxycarbonyl, where the alkyl groups can optionally be substituted by an amino group, a natural or unnatural amino acid residue, imino acid residue, optionally N-(C1-Ce)-alkylated or (CB-C1,)-aryl-(Ci C8)-alkylated azaamino acid residue or a dipeptide residue, in which the peptide bond can be reduced to NH-CH2; and R° denotes hydrogen, (C1-Cle)-alkyl, (Ce-C1~)-aryl or ( Cs-Cu ) -aryl- ( C1-Ce ) -alkyl ;
and their physiologically tolerable salts.
Alkyl radicals can be straight-chain or branched.
Preferred alkyl radicals are methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and tert-butyl. The same applies to radicals such as alkoxy, alkoxycarbonyl or aralkyl.
(C3-CB)-Cycloalkyl radicals are in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which, however, can also be substituted by, for example, (C1-C4)-alkyl. Examples of substituted cycloalkyl radicals are 4-methylcyclohexyl and 2,3-dimethylcyclopentyl.
(Ce-Cl,)-Aryl groups are, for example, phenyl, naphthyl, biphenylyl or fluorenyl, phenyl and naphthyl being preferred. The same applies to radicals such as aralkyl or arylcarbonyl. Aralkyl radicals are in particular benzyl and also 1- and 2-naphthylmethyl, which can also be substituted. Substituted aralkyl radicals are, for example, halobenzyl or ( C1-C4 ) -alkoxybenzyl .
If phenyl is disubstituted, the substituents can be present in the 1,2-, 1,3- or 1,4-position to one another. The 1,3- and the 1,4-positions are preferred.
Heterocycles within the meaning of the above definitions ~~~~~'~'~3 ~tef.3507 ne0045 are, for example, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, isoindazolyl, indazolyl, phthalazinyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl or a benzo-fused, cyclopenta-, cyclohexa- or cyclohepta-fused derivative of these radicals.
These heterocycles can be substituted on a nitrogen atom by oxides, (C1-C~)-alkyl, for example methyl or ethyl, phenyl or phenyl-(C1-C,)-alkyl, for example benzyl, and/or on one or more carbon atoms by (C1-C,)-alkyl, halogen, hydroxyl, (C1-C,)-alkoxy, for example methoxy, phenyl-(Ci-C,)-alkoxy, for example benzyloxy, or oxo and can be partially or completely saturated.
Radicals of this type are, for example, 2- or 3-pyrrolyl, phenylpyrrolyl, for example 4- or 5-phenyl-2-pyrrolyl, 2-furyl, 2-thienyl, 4-imidazolyl, methylimidazolyl, for example 1-methyl-2-, 4- or 5-imidazolyl, 1,3-thiazol-2-yl, 2-, 3- or 4-pyridyl, 2-, 3- or 4-pyridyl-N-oxide, 2-pyrazinyl, 2-, 4- or 5-pyrimidinyl, 2-, 3- or 5-indolyl, substituted 2-indolyl, for example 1-methyl-, 5-methyl-, 5-methoxy, 5-benzyloxy, 5-chlorine or 4,5-dimethyl-2-indolyl, 1-benzyl-2- or 3-indolyl, 4,5,6,7-tetrahydro-2-indolyl, cyclohepta[b]-5-pyrrolyl, 2-, 3- or 4-quinolyl, 1-, 3- or 4-isoquinolyl, 1-oxo-1,2-dihydro-3-isoquinolyl, 2-quinoxylinyl, 2-benzofuranyl, 2-benzothienyl, 2-benzoxazolyl or benzothiazolyl. Partially hydrogenated or completely hydrogenated heterocyclic rings are, for example, dihydropyridinyl, pyrrolidinyl, for example 2-, 3- or 4-N-methylpyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl, benzodioxolanyl.
Halogen represents fluorine, chlorine, bromine or iodine, in particular fluorine or chlorine.
Natural and unnatural amino acids can be present, if they are chiral, in the D- or L-form. a-Amino acids are preferred. For example, the following may be mentioned (cf. Houben-Weyl, Methoden der organischen Chemie (Methods of organic chemistry), Volume XV/1 and 2, Stuttgart, 1974):
Aad, Abu BAbu, ABz, 2ABz, Aca, Ach, Acp, Adpd, Ahb, Aib, Ref . 3507 ne0045 pAib, Ala, pAla, nAla, Alg, All, Ama, Amt, Ape, Apm, Apr, Arg, Asn, Asp, Asu, Aze, Azi, Bai, Bph, Can, Cit, Cys, (Gys)2, Cyta, Daad, Dab, Dadd, Dap, Dapm, Dasu, Djen, Dpa, Dtc, Fel, Gln, Glu, Gly, Guv, hAla, hArg, hCys, hGln, hGlu, His, hIle, hLeu, hLys, hMet, hPhe, hero, hSer, hThr, hTrp, hTyr, Hyl, Hyp, 3Hyp, Ile, Ise, Iva, Kyn, Lant, Lcn, Leu, Lsg, Lys, pLys, ~Lys, Met, Mim, Min, nArg, Nle, Nva, Oly, Orn, Pan, Pec, Pen, Phe, Phg, Pic, Pro, nPro, Pse, Pya, Pyr, Pza, Qin, Ros, Sar, Sec, Sem, Ser, Thi, ,BThi, Thr, Thy, Thx, Tia, Tle, Tly, Trp, Trta, Tyr, Val, Tbg, Npg, Chg, Cha, Thia, 2,2-diphenylaminoacetic acid, 2-(p-tolyl)-2-phenylaminoacetic acid and 2-(p-chlorophenyl)aminoacetic acid.
Amino acid side chains are understood as meaning side chains of natural or unnatural amino acids. Azaamino acids are natural or unnatural amino acids, the central component -CHR- or -CH2- being replaced by -NR- or -NH- respectively.
Suitable radicals of an imino acid are in particular radicals of heterocycles from the following groups Pyrrolidine-2-carboxylic acid; piperidine-2-carboxylic acid; tetrahydroisoquinoline-3-carboxylic acid;
decahydroisoquinoline-3-carboxylic acid; octahydroindole-2-carboxylic acid; decahydroquinoline-2-carboxylic acid;
octahydrocyclopenta[b]pyrrole-2-carboxylic acid; 2-aza-bicyclo-[2.2.2]octane-3-carboxylic acid; 2-azabicyclo[2.2.1]heptane-3-carboxylic acid; 2-azabicyclo[3.1.0]hexane-3-carboxylic acid;
2S 2-azaspiro[4.4]nonane-3-carboxylic acid; 2-azaspiro[4.5]decane-3-carboxylic acid; spiro(bicyclo[2.2.1]-heptane)-2,3-pyrrolidine-5-carboxylic acid; spiro(bicyclo[2.2.2]octane)-2,3-pyrrolidine-5-carboxylic acid; 2-azatricyclo[4.3.O.lg'9]-decane-3-carboxylic acid; decahydrocyclohepta[b]pyrrole-2-carboxylic acid;
decahydrocycloocta[c]pyrrole-2-carboxylic acid; octahydro-cyclopenta[c]pyrrole-2-carboxylic acid; octahydroisoindole-1-carboxylic acid; 2,3,3a,4,6a-hexahydrocyclopenta[b]pyrrole-2-carboxylic acid; 2,3,3a,4,5,7a-hexahydroindole-2-carboxylic acid; tetrahydrothiazole-4-carboxylic-acid; isoxazolidine-3-carboxylic acid; pyrazolidine-3-carboxylic acid;
hydroxyproline-2-carboxylic acid; which can all be optionally substituted (see the following formulae):
.ef . 3507 ne0045 ~CC_ ; ~ i Ca-Ca- Ca°
i ; ~Ca 1 ~!~~,r~~*""~ 1 *oa- ~Lv~-~ tvv° 1 1 , ' 1 C~-~ v Cv" ; ~~;.°v~- ; , N
TT~e~~ 1 ~Ca° ! *Ca-.; ~~''C° 1 I i ~~ N
eV
-Va- i N '~
~' ca- i ca- i ~~ca- ; ' N *ca- ; ~ca- i N
t 1 , NO
*Ca- i N~eC ' ~°Ca- i i The heterocycles on which the abovementioned radicals are based are known, for example, from US-A 4,344,949; US-A 4,374,847; US-A 4,350,704; EP-A 29,488;
EP-A 31,741; EP-A 46,953; EP-A 49,605; EP-A 49,658; EP-A 50,800;
EP-A 51,020; EP-A 52,870; EP-A 79,022; EP-A 84,164; EP-A 89,637;
EP-A 90,341; EP-A 90,362; EP-A 105,102; EP-A 109,020;
EP-A 111,873; EP-A 271,865 and EP-A 344,682.
_ ' CA 02094773 2002-11-22 ~-~~,"g~zolidine~ derivat:~,vgrs The present invention relates to 2,4-dioaoimidazolidine derivatives, their preparation aad their nse as inhibitors of blood platelet aggregation.
Hydaatoin derivatives having thraa~bocyte aggregation-inhibiting action are described in EP-A 449,079, aad in the uapublished Germaa Patent Application p 41 2s 2'7.8.
published on February 13, 2002, publication number DE-A 41 26 277. Further research has shown that the compounds of the present invention are also gotent inhibitors of blood platelet aggregation.
The present invention relates to compounds of the general formula I.
caaH
H I
R 1-.C~ I H 2 4 H-lf-N H'-C"tt R 2-i~l~ I 3 a R
In whlCh Y deaotes -(CHs):-C~-, where m represeats as integer from 1 to 4, or n v ~ , Rl denotes - ( CHZ ) n NH-X, where n represents an integer from I t0 6, - ( CHZ ) p-C6H,-NH-X, - ( CHZ ) p-CaH,-C (=NH ) 'NHZ Or - ( CHZ ) p-C6H~-C&~-NB-X, where p in each case represents 1 or 2 , but also where instead of C H-~R 1 C'~C H~C 6114-x 1 can be present;
%1 deaotes -NBX, -CHI or -C(=HH)-HH=i 8 deaotes hydrogen, (Ci C6)-alkyl or a radical of the formula II
r Ref.3507 ne0045 2G9~~'~'~3 R' -NH-C~1-R "
where R' and R " independently of one another represent hydrogen or (C1-Cs)-alkyl;
R2 denotes hydrogen or (Cl-Cs)-alkyl;
R3 denotes hydrogen or phenyl;
R' denotes -COORS, CO-N ( C83 ) -RS or -CO-NH-R5;
Rs denotes (C1-C2g)-alkyl which is substituted a) by mono- or di-(C1-Cls)-alkylaminocarbonyl, amino-( CZ Cl' ) -alkylaminocarbonyl, amino- ( Ci C3 ) -alkylphenyl-(Cl-C3)-alkylaminocarbonyl, (C1-Cls)-alkylcarbonylamino-(Ci-C3)-alkylphenyl-(C1-C3)-alkylaminocarbonyl or (Ci-Cle)-alkylcarbonylamino-(C2-C1')-alkylaminocarbonyl, where the alkyl radicals for their part can be substituted by hydroxyl, amino, mercapto, (C1-Cis)-alkoxy, halogen, vitro, trifluoromethyl, ( Cs-C1' ) -aryl or ( Cs-C1' ) -aryl- ( C1-Ca ) -alkyl and which b) is optionally additionally monosubatituted or polysubstituted by identical or different radicals from the series consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, amino, mercapto, ( C1-Cls ) -alkoxy, ( C1-Cls ) -alkoxycarbonyl, ( Cs-C1' ) -aryl-(Cl-C3)-alkoxycarbonyl, (C3-Cs)-cycloalkyl, halogen, vitro, trifluoromethyl and a radical Rs;
Rs denotes ( Cs-C1' ) -aryl, ( Cs-Cl' ) -aryl- ( C1-Cs ) -alkyl , a monocyclic or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which, as the heteroelement, can contain one, two or three identical or different nitrogen, oxygen or sulphur atoms, or denotes a radical R~, where the aryl radical and, independently thereof, the heterocyclic radical can be optionally monoaubstituted or polyaubstituted by identical or different radicals from the series consisting of (C1-ClBj-alkyl, (C1-Cls)-alkoxy, halogen, vitro and trifluoromethyl;
R' denotes -NRBRs, -ORs, -SRs, an amino acid side chain, a natural or unnatural amino acid residue, imino acid residue, optionally N- ( C1-Ce ) -alkylated or ( Cs-C1, ) -aryl- ( C1-Ce ) -alkylated azaamino acid residue or dipeptide residue, in which the peptide Ref.3507 ' ne0045 bond can be~reduced to NH-CH2, and also their esters and amides, where free functional groups can optionally be substituted by hydrogen or hydroxymethyl or be protected by protective groups customary in peptide chemistry, or denotes a radical -COR'', in which R'~ is defined as R';
Re denotes hydrogen, ( C2-C18 ) -alkyl, ( CB-C1, ) -aryl-(C1-Ce)-alkyl, (Cl-Cle)-alkylcarbonyl, (Cl-C18)-alkoxycarbonyl, ( Cs-C1, ) -arylcarbonyl, ( Cs-C1, ) -aryl- ( C1-Ce ) -alkylcarbonyl, or (CB-Cl,)-aryl-(C1-C18)-alkoxycarbonyl, where the alkyl groups can optionally be substituted by an amino group, a natural or unnatural amino acid residue, imino acid residue, optionally N-(C1-Ce)-alkylated or (CB-C1,)-aryl-(Ci C8)-alkylated azaamino acid residue or a dipeptide residue, in which the peptide bond can be reduced to NH-CH2; and R° denotes hydrogen, (C1-Cle)-alkyl, (Ce-C1~)-aryl or ( Cs-Cu ) -aryl- ( C1-Ce ) -alkyl ;
and their physiologically tolerable salts.
Alkyl radicals can be straight-chain or branched.
Preferred alkyl radicals are methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl and tert-butyl. The same applies to radicals such as alkoxy, alkoxycarbonyl or aralkyl.
(C3-CB)-Cycloalkyl radicals are in particular cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, which, however, can also be substituted by, for example, (C1-C4)-alkyl. Examples of substituted cycloalkyl radicals are 4-methylcyclohexyl and 2,3-dimethylcyclopentyl.
(Ce-Cl,)-Aryl groups are, for example, phenyl, naphthyl, biphenylyl or fluorenyl, phenyl and naphthyl being preferred. The same applies to radicals such as aralkyl or arylcarbonyl. Aralkyl radicals are in particular benzyl and also 1- and 2-naphthylmethyl, which can also be substituted. Substituted aralkyl radicals are, for example, halobenzyl or ( C1-C4 ) -alkoxybenzyl .
If phenyl is disubstituted, the substituents can be present in the 1,2-, 1,3- or 1,4-position to one another. The 1,3- and the 1,4-positions are preferred.
Heterocycles within the meaning of the above definitions ~~~~~'~'~3 ~tef.3507 ne0045 are, for example, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, isoindazolyl, indazolyl, phthalazinyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl or a benzo-fused, cyclopenta-, cyclohexa- or cyclohepta-fused derivative of these radicals.
These heterocycles can be substituted on a nitrogen atom by oxides, (C1-C~)-alkyl, for example methyl or ethyl, phenyl or phenyl-(C1-C,)-alkyl, for example benzyl, and/or on one or more carbon atoms by (C1-C,)-alkyl, halogen, hydroxyl, (C1-C,)-alkoxy, for example methoxy, phenyl-(Ci-C,)-alkoxy, for example benzyloxy, or oxo and can be partially or completely saturated.
Radicals of this type are, for example, 2- or 3-pyrrolyl, phenylpyrrolyl, for example 4- or 5-phenyl-2-pyrrolyl, 2-furyl, 2-thienyl, 4-imidazolyl, methylimidazolyl, for example 1-methyl-2-, 4- or 5-imidazolyl, 1,3-thiazol-2-yl, 2-, 3- or 4-pyridyl, 2-, 3- or 4-pyridyl-N-oxide, 2-pyrazinyl, 2-, 4- or 5-pyrimidinyl, 2-, 3- or 5-indolyl, substituted 2-indolyl, for example 1-methyl-, 5-methyl-, 5-methoxy, 5-benzyloxy, 5-chlorine or 4,5-dimethyl-2-indolyl, 1-benzyl-2- or 3-indolyl, 4,5,6,7-tetrahydro-2-indolyl, cyclohepta[b]-5-pyrrolyl, 2-, 3- or 4-quinolyl, 1-, 3- or 4-isoquinolyl, 1-oxo-1,2-dihydro-3-isoquinolyl, 2-quinoxylinyl, 2-benzofuranyl, 2-benzothienyl, 2-benzoxazolyl or benzothiazolyl. Partially hydrogenated or completely hydrogenated heterocyclic rings are, for example, dihydropyridinyl, pyrrolidinyl, for example 2-, 3- or 4-N-methylpyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydrothienyl, benzodioxolanyl.
Halogen represents fluorine, chlorine, bromine or iodine, in particular fluorine or chlorine.
Natural and unnatural amino acids can be present, if they are chiral, in the D- or L-form. a-Amino acids are preferred. For example, the following may be mentioned (cf. Houben-Weyl, Methoden der organischen Chemie (Methods of organic chemistry), Volume XV/1 and 2, Stuttgart, 1974):
Aad, Abu BAbu, ABz, 2ABz, Aca, Ach, Acp, Adpd, Ahb, Aib, Ref . 3507 ne0045 pAib, Ala, pAla, nAla, Alg, All, Ama, Amt, Ape, Apm, Apr, Arg, Asn, Asp, Asu, Aze, Azi, Bai, Bph, Can, Cit, Cys, (Gys)2, Cyta, Daad, Dab, Dadd, Dap, Dapm, Dasu, Djen, Dpa, Dtc, Fel, Gln, Glu, Gly, Guv, hAla, hArg, hCys, hGln, hGlu, His, hIle, hLeu, hLys, hMet, hPhe, hero, hSer, hThr, hTrp, hTyr, Hyl, Hyp, 3Hyp, Ile, Ise, Iva, Kyn, Lant, Lcn, Leu, Lsg, Lys, pLys, ~Lys, Met, Mim, Min, nArg, Nle, Nva, Oly, Orn, Pan, Pec, Pen, Phe, Phg, Pic, Pro, nPro, Pse, Pya, Pyr, Pza, Qin, Ros, Sar, Sec, Sem, Ser, Thi, ,BThi, Thr, Thy, Thx, Tia, Tle, Tly, Trp, Trta, Tyr, Val, Tbg, Npg, Chg, Cha, Thia, 2,2-diphenylaminoacetic acid, 2-(p-tolyl)-2-phenylaminoacetic acid and 2-(p-chlorophenyl)aminoacetic acid.
Amino acid side chains are understood as meaning side chains of natural or unnatural amino acids. Azaamino acids are natural or unnatural amino acids, the central component -CHR- or -CH2- being replaced by -NR- or -NH- respectively.
Suitable radicals of an imino acid are in particular radicals of heterocycles from the following groups Pyrrolidine-2-carboxylic acid; piperidine-2-carboxylic acid; tetrahydroisoquinoline-3-carboxylic acid;
decahydroisoquinoline-3-carboxylic acid; octahydroindole-2-carboxylic acid; decahydroquinoline-2-carboxylic acid;
octahydrocyclopenta[b]pyrrole-2-carboxylic acid; 2-aza-bicyclo-[2.2.2]octane-3-carboxylic acid; 2-azabicyclo[2.2.1]heptane-3-carboxylic acid; 2-azabicyclo[3.1.0]hexane-3-carboxylic acid;
2S 2-azaspiro[4.4]nonane-3-carboxylic acid; 2-azaspiro[4.5]decane-3-carboxylic acid; spiro(bicyclo[2.2.1]-heptane)-2,3-pyrrolidine-5-carboxylic acid; spiro(bicyclo[2.2.2]octane)-2,3-pyrrolidine-5-carboxylic acid; 2-azatricyclo[4.3.O.lg'9]-decane-3-carboxylic acid; decahydrocyclohepta[b]pyrrole-2-carboxylic acid;
decahydrocycloocta[c]pyrrole-2-carboxylic acid; octahydro-cyclopenta[c]pyrrole-2-carboxylic acid; octahydroisoindole-1-carboxylic acid; 2,3,3a,4,6a-hexahydrocyclopenta[b]pyrrole-2-carboxylic acid; 2,3,3a,4,5,7a-hexahydroindole-2-carboxylic acid; tetrahydrothiazole-4-carboxylic-acid; isoxazolidine-3-carboxylic acid; pyrazolidine-3-carboxylic acid;
hydroxyproline-2-carboxylic acid; which can all be optionally substituted (see the following formulae):
.ef . 3507 ne0045 ~CC_ ; ~ i Ca-Ca- Ca°
i ; ~Ca 1 ~!~~,r~~*""~ 1 *oa- ~Lv~-~ tvv° 1 1 , ' 1 C~-~ v Cv" ; ~~;.°v~- ; , N
TT~e~~ 1 ~Ca° ! *Ca-.; ~~''C° 1 I i ~~ N
eV
-Va- i N '~
~' ca- i ca- i ~~ca- ; ' N *ca- ; ~ca- i N
t 1 , NO
*Ca- i N~eC ' ~°Ca- i i The heterocycles on which the abovementioned radicals are based are known, for example, from US-A 4,344,949; US-A 4,374,847; US-A 4,350,704; EP-A 29,488;
EP-A 31,741; EP-A 46,953; EP-A 49,605; EP-A 49,658; EP-A 50,800;
EP-A 51,020; EP-A 52,870; EP-A 79,022; EP-A 84,164; EP-A 89,637;
EP-A 90,341; EP-A 90,362; EP-A 105,102; EP-A 109,020;
EP-A 111,873; EP-A 271,865 and EP-A 344,682.
.ef . 3507 ne0045 Dipeptides can contain natural or unnatural amino acids, imino acids and also azaamino acids as components. The natural or unnatural amino acids, imino acids, azaamino acids and dipeptides can furthermore also be present as esters or amides, such as, for example, methyl ester, ethyl amide, semicarbazide or w-amino-(C~-CB)-alkyl amide.
Functional groups of the amino acids, imino acids and dipeptides can be present in protected form. Suitable protective groups such as, for example, urethane protective groups, carboxyl protective groups and side chain protective groups are described in $ubbuch, Kontakte (Merck) 1979, No. 3, pages 14 to 23 and in Btillesbach, Kontakte (Merck) 1980, No. 1, pages 23 to 35. The following may be mentioned in particular: Aloc, Pyoc, Fmoc, Tcboc, Z, Hoc, Ddz, Bpoc, Adoc, MSC, Moc, Z(NOZ), Z($aln), Hobz, Iboc, Adpoc, Mboc, Acm, tert-butyl, OBzl, ONbzl, OMbzl, Bzl, Mob, Pic, Trt.
Physiologically tolerable salts of the compounds of the general formula I are in particular pharmaceutically utilisable or non-toxic salts.
Such salts are formed, for example, from compounds of the general formula I which contain acidic groups, for example carboxyl, using alkali metals or alkaline earth metals, such as, for example, Na, K, Mg and Ca, and also with physiologically tolerable organic amines, such as, for example, triethylamine and tris(2-hydroxyethyl)amine.
Compounds of the general formula I which contain basic groups, for example an amino group or a guanidino group, form salts with organic acids, such as, for example, hydrochloric acid, sulphuric acid or phosphoric acid and with organic carboxylic or sulphonic acids, such as, for example, acetic acid, citric acid, benzoic acid, malefic acid, fumaric acid, tartaric acid and p-toluenesulphonic acid.
Preferred compounds of the general formula I are those in which Y denotes -(C$2)m CO-, where m represents 1 or 2, or ~~~~~~J
''ef . 3507 ..e0045 Rl denotes -CHz-C6H4-NH-C (=NH ) -NHz; -CHZ-C6H4-C (=NH ) -NHZ or -CHZ-CsH4-CHZ-NH2;
RZ denotes hydrogen or methyl;
R3 denotes hydrogen; and R° denotes -CO-NH-R5, where -NH-RS represents an ~-amino-(CZ-CB)-alkyl amide of an a-amino acid residue.
-NH-RS is particularly preferably represented by the 4-aminobutyl amide of the valine, lysine, phenylalanine or phenylglycine residues.
The compounds of the general formula I according to the invention can be prepared by fragment condensation of a compound of the general formula III
H
R1 ~~
N-Y-OH (III) with a compound of the general formula IV
COON
(IV) where the radicals R1 to R° and Y are defined as indicated above.
For condensation of the compounds of the general foranula III with those of the general formula IV, the methods of peptide chemistry known per se are advantageously used (see, for example, Houben-Weyl, Methoden der organischen Chemie (Methods of organic chemistry), Volume 15/1 and 15/2, Stuttgart, 1974).
To do this, it is necessary as a rule that amino groups contained in R1 and R' are protected by reversible protective groups. The same applies to the carboxyl groups of the compound of the general formula IV, which is preferably present as a benzyl or tart-butyl ester. Protection of amino groups is g -Ref.3507 e0045 unnecessary if the amino groups to be generated are present as nitro or cyano groups and are only formed after coupling by hydrogenation.
After coupling, the protective groups present are removed in a suitable manner. For example, N02 groups (guanidino protection), benzyloxycarbonyl groups and benzyl esters can be removed by hydrogenation. Protective groups of the tert-butyl type are cleaved by acid, while the 9-fluorenylmethoxycarbonyl radical is removed by secondary amines.
The starting compounds of the general formula III can be obtained as follows:
By reaction of amino acids, N-alkylamino acids or preferably their methyl, ethyl, benzyl or tert-butyl esters, for example a compound of the general formula V
~ (v) with an isocyanatoalkanecarboxylic acid ester, for example of the general formula VI
O=C=N- ( CHz ) m COOCH3 ( V I ) in which Rl, RZ and m are defined as indicated above, urea derivatives are obtained, for example of the general formula VII
II I I (VII), CH300C-(CH2)m-NH-C-N-CH-COOCH3 which cyclise by heating with acid with hydrolysis of the ester functions to give compounds of the general formula IIIa H
R 1-C~"
N-tCH2)s-c00H (IIIa) During the urea synthesis, guanidino groups can.be blocked by protective groups, such as NOZ or Mtr. Amino groups in the side chain must likewise be present in protected form (for example as Boc or Z derivatives) or additionally as an N02 or cyano function which can later be reduced to the amino group or, .ef . 3507 ne0045 in the case of the cyano group, also be converted into the formamidino group.
Compounds of the general formula IIIb H COOH
R1 i°'~ , (IIIb) N
can be obtained analogously if, instead of isocyanatoalkanecarboxylic acid esters, the isocyanates of the aminobenzoic acid esters are employed.
Compounds of the general formula IIIc H
-~
X1 ~C~ (IIIc) N-'Y-0 H
R 2-N---~
can be obtained by reaction of hydantoins of the general formula VIII
H
H°C--~~
N-Y-OH (VIII) R 2-N--~
with aldehydes of the general formula IX
H° (Ix) xi analogously to Granacher and Landolt, Helv. Chim. Acta 10 (1927) 808.
Otherwise, hydantoins of the general formula Xa 2~~~~'~'~3 .;ef . 3507 ne0045 R " ~ ~N-C H 2-C-R 1 1 HN---~ (Xa) in which Rl° denotes any desired amino acid side chain and Rli denotes an amide, an amino acid residue or a peptide residue, very commonly result by basic treatment of alkoxycarbonyl 5 peptides or aralkoxycarbonyl peptides of the general formula X
R12-0-CO-NH-CHR1°-CO-NH-CHZ-CO-R11 ( X ) in which Rl° and Rl' are defined as indicated above and R12 denotes benzyl or tert-butyl (J. S. Fruton and M. Bergmann, J. Biol.
Chem. 145 (1942) 253 - 265; C. A. Dekker, S. P. Taylor, jr. and 10 J. S. Fruton, J. Biol. Chem. 180 (1949) 155 - 173; M. E. Cox, H.
G. Carg, J. Hollowood, J. M. Hugo, P. M. Scopes and G. T. Young, J. Chem. Soc. (1965) 6806 - 6813; W. Voelter and A. Altenburg, Liebigs Ann. Chem. (1983) 1641 - 1655; B. Schwenzer, E. Weber and G. Losse, J. Prakt. Chem. 327 (1985) 479 - 486). In this case, however, the N-terminal amino acid racemises and the hydantoin hydrolyses to the urea derivative HOCO-CHR1°-NH-CO-NH-CHZ-CO-Rli (W. Voelter and A. Altenburg, Liebigs Ann. Chem. (1983) 1641 - 1655).
In comparison, a mild method is cyclisation to give the hydantoins from compounds of the general formula X by treatment with tetrabutylammonium fluoride in tetrahydrofuran under reflux (J. Pleas, J. Org. Chem. 39 (1974) 2644 - 2646).
A further possibility of a mild cyclisation is trimethylsilylation of the peptide bond between the N-terminal amino acid and the following glycine using biatrimethylsilyltrifluoroacetamide in acetonitrile (4 hours under reflux) (J. S. Davies, R. K. Merritt and R. C. Treadgold, J. Chem. Soc. Perkin Trans. I (1982) 2939 - 2947).
The guanylation of the amino function can be carried out using the following reagents:
1. O-Methylisothiourea (S. Weiss and H. Krommer, Chemiker Zeitung 98 (1974) 617 - 618), Ref.3507 ~e0045 2. S-Methylisothiourea (R. F. Borne, M. L. Forrester and I. W.
Waters, J. Med. Chem. 20 (1977) 771 - 776), 3. Nitro-S-methylisothiourea (L. S. Hafner and R. E. Evans, J.
Org. Chem. 24 (1959) 1157), 4. Formamidinosulphonic acid (K. Kim, Y.-T. Lin and H. S. Mosher, Tetrah. Lett. 29 (1988) 3183 - 3186), 5. 3,5-Dimethyl-1-pyrazolylformamidinium nitrate (F. L. Scott, D.
G. O~Donovan and J. Reilly, J. Amer. Chem. Soc. 75 (1953) 4053 - 4054).
Formamidines can be prepared from the corresponding cyano compounds by addition of alcohols (for example methanol or ethanol) in acidic anhydrous medium (for example dioxane, methanol or ethanol) and subsequent treatment with ammonia in alcohols (for example isopropanol, methanol or ethanol) (G.
Wagner, P. Richter and Ch. Garbs, Pharmazie 29 (1974) 12 - 55). A
further method of preparing formamidines is the addition of H2S to the cyano group, followed by a methylation of the resulting thioamide and subsequent reaction with ammonia (GDR Patent No.
235,866).
The starting peptides of the general formula IV are as a rule synthesised stepwise from the C-terminal end. Formation of peptide bonds can be carried out using the known coupling methods of peptide chemistry.
The compounds of the general formula I and their physiologically tolerable salts can be administered as medicines per se on their own, in mixtures with one another or in the form of pharmaceutical preparations which permit enteral or parenteral use and which contain, as active constituent, an effective dose of at least one compound of the general formula I or of a salt thereof, in addition to customary pharmaceutically innocuous excipients and additives. The preparations normally contain about 0.5 to 90$ by weight of the therapeutically active compound.
The medicines can be administered orally, for example in the form of pills, tablets, coated tablets, sugar-coated tablets, granules, hard and soft gelatine capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration can also be carried out, however, rectally, for example in the form 20~~~'~'~3 ;ef . 3507 ne0045 of suppositories, or parenterally, for example in the form of injection solutions or microcapsules, percutaneously, for example in the form of ointments or tinctures or nasally, for example in the form of nasal sprays.
The pharmaceutical preparations can be prepared in a manner known per se, pharmaceutically inert inorganic or organic excipients being used. For the preparation of pills, tablets, coated tablets and hard gelatine capsules, lactose, maize starch or derivatives thereof, talc, stearic acid or its salts, etc., for example, can be used. Excipients for soft gelatine capsules and suppositories are, for example, fats, waxes, semi-solid and liquid polyols, natural or hardened oils, etc. Suitable excipients for the preparation of solutions and syrups are, for example, water, sucrose, dextrose, glucose, polyols etc. Suitable excipients for the preparation of injection solutions are water, alcohols, glycerol, polyols or vegetable oils, etc. Suitable excipients for microcapsules or implants are, for example, copolymers of glycolic acid and lactic acid.
Apart from the active compounds and excipients, the pharmaceutical preparations can additionally contain additives such as, for example, fillers, extenders, disintegrants, binders, lubricants, wetting agents, stabilisers, emulsifiers, pre-servatives, sweeteners, colorants, flavourings or aromatisers, thickeners, diluents, buffer substances, and also solvents or solubilisers or agents for achieving a depot effect as well as salts for changing the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the general formula I or their physiologically tolerable salts and additionally one or more other therapeutically active substances.
Other therapeutically active substances of this type are, for example, agents promoting the circulation, such as dihydroergocristine, nicergoline, buphenine, nicotinic acid and its esters, pyridylcarbinol, bencyclan, cinnarizine, naftidrofuryl, raubasine and vincamine; positively inotropic compounds, such as digoxin, acetyldigoxin, metildigoxin and lanthanoglycosides; coronary dilators, such as carbochromen;
dipyramidol, nifedipine and perhexiline; antianginal compounds, Ref . 3507 2 ~ ~ ~~ "~ "~ 3 ze0045 such as isosorbide dinitrate, isosorbide mononitrate, glycerol nitrate, molsidomine and verapamil; ,9-blockers, such as propranolol, oxprenolol, atenolol, metoprolol and penbutolol. The compounds may moreover be combined with other nootropic substances, such as, for example, piracetam, or CNS-active substances, such as pirlindol, sulpiride, etc.
The dose can vary within wide limits and is to be adapted to the individual conditions in each individual case. In general, in the case of oral administration a daily dose of about 0.1 to 1 mg/kg, preferably 0.3 to 0.5 mg/kg, of body weight is appropriate to achieve effective results, in the case of intravenous administration the daily dose is in general about 0.01 to 0.3 mg/kg, preferably 0.05 to 0.1 mg/kg, of body weight.
The daily dose is normally divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. In some cases, depending on individual behaviour, it may be necessary to deviate upwards or downwards from the given daily dose. Pharmaceutical preparations normally contain 0.2 to 50 mg, preferably 0.5 to 10 mg, of active compound of the general formula I or one of its physiologically tolerable salts per dose.
The compounds of the formula I according to the invention have the ability to inhibit cell-cell adhesion which is due to the interaction of Arg-Gly-Asp-containing proteins, such as fibronectin, fibrinogen or the von Willebrand factor, with the so-called integrins. Integrins are transmembrane glycoproteins, receptors for Arg-Gly-Asp-containing cell matrix glycoproteins (E. Ruoslahti and M. D. Pierschbacher, Science 238 (1987) 491 - 497; D. R. Phillips, I. F. Charo, L. V. Parise and L. A.
Fitzgerald, Blood 71 (1988) 831 - 843). They additionally inhibit the binding of other adhesive proteins, such as vitronectin, collagen and laminin, to the corresponding receptors on the surface of various types of cell.
The compounds of the general formula I according to the invention inhibit platelet aggregation, the metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
The hydantoin derivatives of the general formula I are Ref.3507 ne0045 used acutely in risk of thrombosis and chronically in the prevention of arteriosclerosis and thrombosis, for example in the therapy and prophylaxis of arterial vascular diseases, such as in acute myocardial infarct, secondary prevention of myocardial infarct, reocclusion prophylaxis after lysis and dilatation (PCTA), unstable angina pectoris, transitory ischaemic attacks, strokes, coronary bypass operation including bypass reocclusion prophylaxis, pulmonary embolism, peripheral arterial occlusive disease, dissecting aneurysm; in the therapy of venous and microcirculatory vascular disorders, such as deep vein thrombosis, disseminated intravascular clotting, post-operative and post-partum trauma, surgical or infectious shock, septicaemia or in hyperactive platelet diseases, thrombotic thrombocytopenic purpura, preeclampsia, premenstrual syndrome, dialysis or extracorporeal circulation; a further use is during cancer operations and also prophylactically in cancer. Osteoporosis can also be prevented by inhibition of osteoclast binding to the bone surface.
The compounds are tested in particular for their inhibitory action in blood platelet aggregation and the adhesion of fibrinogen to blood platelets. Gel-filtered blood platelets from human donor blood are used, which are activated with ADP or thrombin.
Examples:
The products were identified by means of mass spectra and/or NMR spectra.
Example l:
(5-(S)-(3-Guanidinopropyl)-2,4-dioxoinidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (4-aminobutyl) amide acetate la: Z-Phe-NH-(CHZ),-NH-Boc 5.98 g (20 mmol) of N-benzyloxycarbonyl-L-phenylalanine and 4.49 g (20 mmol) of 4-(tert-butoxycarbonylamino)butylamine hydrochloride are dissolved in 100 ml of dimethylformamide and cooled to 0°C in an ice-bath. After addition of 2.7 g (20 mmol) of hydroxybenzotriazole, 4.4 g (20 mmol) of DCCI and 2.54 ml Ref . 3507 ne0045 (20 mmol).of N-ethylmorpholine, the reaction is stirred overnight. The precipitated urea is filtered off with suction and the solution is evaporated in a high vacuum. The residue is taken up in 200 ml of ethyl acetate and the organic phase is extracted with water, sodium hydrogen carbonate solution and potassium hydrogen sulphate solution and dried over magnesium sulphate.
After filtration and concentration, 8.2 g (87%) of amorphous product are obtained.
1b: H-Phe-NH-(CHZ)~-NH-Hoc hydrochloride 8.2 g (1?.5 mmol) of Z-Phe-NH-(CH2),-NH-Hoc are dissolved in 300 ml of methanol and treated with 1.5 g of Pd/C. Hydrogen is then introduced and the pH is maintained at 4 by addition of methanolic hydrochloric acid. After completion of the reaction, the mixture is filtered and the filtrate is evaporated. After triturating with ether, 6.5 g (100%) of amorphous product are obtained.
lc: H-L-Aspartyl(OtHu)-L-phenylalanine-NH-(CHZ),-NH-Hoc hydrochloride 5.6 g (1?.4 mmol) of Z-Asp(OtBu)-OH and 6.5 g (17.5 mmol) of H-Phe-NH-(CHZ),-NH-Boc hydrochloride are dissolved in 100 ml of dimethylformamide. After addition of 2.3 g (17 mmol) of hydroxybenzotriazole, 4.4 g (21.3 mmol) of nCCI and 2.2 ml (17.3 mmol) of N-ethylmorpholine, the reaction is stirred overnight. After completion of the reaction, the mixture is concentrated in vacuo. The residue is taken up in ethyl acetate and the organic phase is extracted with water and sodium hydrogen carbonate solution and then dried using magnesium sulphate. After filtration and concentration, 9.7 g of crude product are obtained, which is purified by chromatography.
The combined fractions are hydrogenated as described in 1b. The residue from the hydrogenation is dissolved in 50 ml of ethyl acetate and precipitated using petroleum ether. 4.9 g are obtained.
FAB-MS 507.3 (M+H)+
1d: 5-(S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl L-aspartyl(OtBu)-L-phenylalanine (4-Hoc-aminobutyl) amide 977 mg (1.8 mmol) of H-L-aspartyl(OtBu)-L-phenylalanine-Ref.3507 ne004 U .~ !5 NH-(CHZ),-N-H-Boc hydrochloride and 500 mg of 5-(S)-(3-guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetic acid are dissolved in 5 ml of dimethylformamide. 243 mg (1.8 mmol) of hydroxybenzotriazole and 412 mg (2 mmol) of DCCI are added to the solution and it is stirred overnight. After completion of the reaction, the solution is concentrated and the residue is chromatographed on silica gel without further treatment (eluent:
CHZC12, CH30H, acetic acid, water = 85:10:2.5:2.5). 1.03 g (76%) of product are isolated.
FAB-MS 746.6 (M+H)'' 1e: (5-(S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (4-aminobutyl) amide acetate 1 g (1.38 mmol) of 5-(S)-(3-guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl(OtBu)-L-phenylalanine 4-Boc-aminobutyl amide are stirred at room temperature for 1 hour in 15 ml of 90% strength aqueous trifluoroacetic acid. The solution is then concentrated, the residue is taken up in water and the solution is treated with ion exchanger IRA-93 until a pH of 4 is obtained. The solution is freeze-dried and the residue (880 mg) is chromatographed on Sephadex LH20 using 1 M acetic acid. After concentration and freeze-drying, 735 mg (90%) of product are obtained.
FAB-MS 590.1 (M+H)'"
Example 2:
(5-(S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl L-aspartyl-L-phenylalanine (6-aminohexyl) amide acetate This compound was prepared analogously to the method described in Example 1.
FAB-MS 618.1 (M+H)+
Example 3:
(5-(S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (8-aminooctyl) amide acetate This compound was prepared analogously to the method describd in Example 1.
FAB-MS 646 (M+H)"
2 (~ ~ ~ '~ '~ 3 .tef . 3507 ne0045 Example 4:
(5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (4-aminobutyl) amide acetate This compound was prepared analogously to the method described in Example 1.
FAB-MS 623 (M+H)+
Example 5:
(5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (6-aminohexyl) amide acetate This compound was prepared analogously to the method described in Example 1.
FAB-MS 651 (M+H)r Example 6:
(5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (8-aminooctyl) amide acetate This compound was prepared analogously to the method described in Example 1.
FAB-MS 679 (M+H)'' Example 7:
(5-(R,S)-(4-Formamidino-benzyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-lysine (4-aminobutyl) amide 7a: H-Aspartyl(OtHu)-L-lysine(Hoc)-NH-(CHZ),-NH-Hoc hydrochloride 1.17 ml of N-ethylmorpholine and 1.98 g of DCCI are added at 0°C to a solution of 5.3 g of H-Lys(Boc)-NH-(CHZ),-NH-Boc tosylate, 2.91 g of Z-Asp(OtBu)-OH and 1.21 g of hydroxybenzotriazole in 20 ml of dimethylformamide. The mixture is stirred at 0°C for 1 hour and at room temperature for 4 hours and allowed to stand overnight at room temperature. The precipitate is filtered off with suction and the filtrate is concentrated in vacuo. The residue is partitioned between ethyl acetate and water. The organic phase is extracted with sodium hydrogen carbonate solution, potassium hydrogen sulphate solution and water and dried over sodium sulphate and concentrated. The z I t1 I II
. . CA 02094773 2002-11-22 residue is triturated with ether and filtered off with suction.
The product obtained (5.2 g) is dissolved in 150 ml of methaaol and catalytically hydrogenated over Pd/carbon at pH 4.5 using methanolic hydrochloric acid in as autoburette. After reaction waa complete, the catalyst was filtered off with suction aad the filtrate was concentrated.
Yield: 4.12 g of amorphous substance a)az' _ +3.9° (c = 1, methanol) 7b: (5-(R,S)-(4-Fotmamidiaobeazyl)-2,4-diouo~midazoh.din-3-yl)acetyl-L-aspartpl(OtBn)-L-lpsiae(Hoc) (4-Hoc-~ei.,aobntyl) amide 1.I g of DCCI are added at 0°C to a suspension of 1.54 g of (5-(R,S)-(4-fo~~m~dinobenzyl)-2,4-dioxoimidazolidin-3-yl) acetic acid, 3.1 g of H-aspartyl(OtBu)-L-lysine(Boc)-NH-(CHZ)"-NH-Boc hydrochloride and 675 mg of hydroxybenzotriazole in 20 ml of dimethylfo~~~~~de. The mixture is stirred at 0°C for 1 hour and at room temperature for 4 hours and allowed to stand overnight at room temperature. The precipitate is filtered off with suction and the filtrate is conceatrated in vacuo. For purification, the substance is chromatographed on silica gel in methylene chloride/methanol/water/acetic acid = 8.5:1.5:0.2:0.Z.
Yield: 3.26 g of amorphous substance a ) Dzo = -2 8 7 0 ( C ~ 1, methanol ) 7c: (5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoimidazolidia-3-yl)acetyl-L-aspartyl-L-lysine (4-aminobatyl) amide diacetate 3.15 g of (5-(R, S)-(4-fo~~m~dinobenzylj-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl(Oteu)-L-lysine(Boc) (4-Boc-aminobutyl) amide are dissolved in 30 ml of 90% strength aqueous trifluoroacetir acid. After one houz at room temperature-the mixture is concentrated in vacuo and the residue is partitioned between water and diethyl ether. The aqueous phase °
(30 ml) is chroiaatographed on 50 ml of Amberlite iA 93 (acetate form) and water as the eluent. The eluate is lyophilised and gives 2.42 g of substance. For purification, the substance is chramatographed on Sephadex L&20 (200 x 4 cm) in a mixture of acetic acid, n-butanol and water. The fractions containing pure substance are concentrated, dissolved in water and freeze-dried *Trade-mark r Ref.3507 ne0045 Yield 2.27 g a)p2' _ -35.2° (c = 1, water) Example 8:
(5-(R,S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-valine (4-aminobutyl) amide This compound was prepared analogously to the method described in Example 1.
FAB-MS 541 (M+H)'' Example 9:
(5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoiaidazolidin-3-yl)acetyl-L-aspartyl-L-phenylglycine (4-aminobutyl) amide This compound was prepared analogously to the method described in Example 1.
FAB-MS 608 (M+H)'' Example A:
Emulsions containing 3 mg of active compound per 5 ml can be prepared according to the following recipe:
Active compound 0.06 g Neutral oil q.s.
sodium carboxymethylcellulose 0.6 g Polyoxyethylene stearate q.s.
Pure glycerol 0.6 to 2 g Aromatics q.s.
Water (demineralised or distilled) to 100 ml ~Ref.3507 ne0045 Example B:
Tablets can be prepared according to the following formulation:
Active compound 2 mg Lactose 60 mg Maize starch 30 mg Soluble starch 4 mg Magnesium stearate 4 mg 100 mg 8xample C:
The following composition is suitable for the preparation of soft gelatine capsules containing 5 mg of active compound per capsule:
Active compound 5 mg Mixture of triglycerides from coconut oil 150 mg Capsule contents . 155 mg Example D:
The following formulation is suitable for the preparation of sugar-coated teblets:
Active compound 3 mg Maize starch 100 mg Lactose 55 mg Sec. calcium phosphate 30 mg Soluble starch 3 mg Magnesium stearate 5 mg Colloidal silica 4 mg 200 mg Example E:
Sugar-coated tablets containing an active compound according to the invention and another therapeutically active substance:
Ref . 3507 ne0045 Active compound 6 mg Propanolol 40 mg Lactose 90 mg Maize starch 90 mg Sec. calcium phosphate 34 mg Soluble starch 3 mg Magnesium stearate 3 mg Colloidal silica 4 mg 270 mg Example F:
Sugar-coated tablets containing an active compound according to the invention and another therapeutically active substance:
Active compound 5 mg Pirlindol 5 mg Lactose 60 mg Maize starch 90 mg Sec. calcium phosphate 30 mg Soluble starch 3 mg Magnesium stearate 3 mg Colloidal silica 4 mg 200 mg Example G:
Capsules containing an active compound according to the invention and another therapeutically active substance:
Active compound 5 mg Nicergoline 5 mg Maize starch 185 mg 195 mg Example H: ' Injection solutions containing 1 mg of active compound per ml can be prepared according to the following recipe:
~ef.3507 ne0045 Active compound 1.0 mg Polyethylene glycol 400 0.3 mg Sodium chloride 2.7 mg Water for injection purposes to 1 ml Pharmacological data:
The inhibition of the binding of fibrinogen to its receptor (glycoprotein IIb/IIIa) by the compounds according to the invention is tested on intact, gel-filtered human platelets.
The R~ value of the inhibition of binding of '2sI-fibrinogen after stimulation with ADP (10 pM) is given.
References:
J.S. Bennett and G. Vilaire, J. Clin. Invest. 64 (1979), E. Kornecki et al., J. Biol. Chem. 256 (1981), 5695-5701 G.A. Marguerie et al., J. Biol. Chem. 254 (1979), 5357-5363 G.A. Marguerie et al., J. Biol. Chem. 255 (1980), 154-161 8xample Rs (~M), ADP-stimulated 1 2.50 2 2.44 3 3.21 4 0.32 7 0.17 As a functional test, the inhibition of aggregation of gel-filtered human platelets by the compounds according to the invention is measured after ADP or thrombin stimulation. The ICso value of the inhibition is given.
Reference:
G.A. Marguerie et al., J. Biol. Chem. 254 (1979), 5357-5363 Ref.3507 ne0045 Bxample ICS ~~~il.
ADP-stimulated Thrombin-stimulated 1 1.5 2.0 2 3.0 3.5 3 5.0 3.0 4 0.45 1.0 7 0.25 0.6
Functional groups of the amino acids, imino acids and dipeptides can be present in protected form. Suitable protective groups such as, for example, urethane protective groups, carboxyl protective groups and side chain protective groups are described in $ubbuch, Kontakte (Merck) 1979, No. 3, pages 14 to 23 and in Btillesbach, Kontakte (Merck) 1980, No. 1, pages 23 to 35. The following may be mentioned in particular: Aloc, Pyoc, Fmoc, Tcboc, Z, Hoc, Ddz, Bpoc, Adoc, MSC, Moc, Z(NOZ), Z($aln), Hobz, Iboc, Adpoc, Mboc, Acm, tert-butyl, OBzl, ONbzl, OMbzl, Bzl, Mob, Pic, Trt.
Physiologically tolerable salts of the compounds of the general formula I are in particular pharmaceutically utilisable or non-toxic salts.
Such salts are formed, for example, from compounds of the general formula I which contain acidic groups, for example carboxyl, using alkali metals or alkaline earth metals, such as, for example, Na, K, Mg and Ca, and also with physiologically tolerable organic amines, such as, for example, triethylamine and tris(2-hydroxyethyl)amine.
Compounds of the general formula I which contain basic groups, for example an amino group or a guanidino group, form salts with organic acids, such as, for example, hydrochloric acid, sulphuric acid or phosphoric acid and with organic carboxylic or sulphonic acids, such as, for example, acetic acid, citric acid, benzoic acid, malefic acid, fumaric acid, tartaric acid and p-toluenesulphonic acid.
Preferred compounds of the general formula I are those in which Y denotes -(C$2)m CO-, where m represents 1 or 2, or ~~~~~~J
''ef . 3507 ..e0045 Rl denotes -CHz-C6H4-NH-C (=NH ) -NHz; -CHZ-C6H4-C (=NH ) -NHZ or -CHZ-CsH4-CHZ-NH2;
RZ denotes hydrogen or methyl;
R3 denotes hydrogen; and R° denotes -CO-NH-R5, where -NH-RS represents an ~-amino-(CZ-CB)-alkyl amide of an a-amino acid residue.
-NH-RS is particularly preferably represented by the 4-aminobutyl amide of the valine, lysine, phenylalanine or phenylglycine residues.
The compounds of the general formula I according to the invention can be prepared by fragment condensation of a compound of the general formula III
H
R1 ~~
N-Y-OH (III) with a compound of the general formula IV
COON
(IV) where the radicals R1 to R° and Y are defined as indicated above.
For condensation of the compounds of the general foranula III with those of the general formula IV, the methods of peptide chemistry known per se are advantageously used (see, for example, Houben-Weyl, Methoden der organischen Chemie (Methods of organic chemistry), Volume 15/1 and 15/2, Stuttgart, 1974).
To do this, it is necessary as a rule that amino groups contained in R1 and R' are protected by reversible protective groups. The same applies to the carboxyl groups of the compound of the general formula IV, which is preferably present as a benzyl or tart-butyl ester. Protection of amino groups is g -Ref.3507 e0045 unnecessary if the amino groups to be generated are present as nitro or cyano groups and are only formed after coupling by hydrogenation.
After coupling, the protective groups present are removed in a suitable manner. For example, N02 groups (guanidino protection), benzyloxycarbonyl groups and benzyl esters can be removed by hydrogenation. Protective groups of the tert-butyl type are cleaved by acid, while the 9-fluorenylmethoxycarbonyl radical is removed by secondary amines.
The starting compounds of the general formula III can be obtained as follows:
By reaction of amino acids, N-alkylamino acids or preferably their methyl, ethyl, benzyl or tert-butyl esters, for example a compound of the general formula V
~ (v) with an isocyanatoalkanecarboxylic acid ester, for example of the general formula VI
O=C=N- ( CHz ) m COOCH3 ( V I ) in which Rl, RZ and m are defined as indicated above, urea derivatives are obtained, for example of the general formula VII
II I I (VII), CH300C-(CH2)m-NH-C-N-CH-COOCH3 which cyclise by heating with acid with hydrolysis of the ester functions to give compounds of the general formula IIIa H
R 1-C~"
N-tCH2)s-c00H (IIIa) During the urea synthesis, guanidino groups can.be blocked by protective groups, such as NOZ or Mtr. Amino groups in the side chain must likewise be present in protected form (for example as Boc or Z derivatives) or additionally as an N02 or cyano function which can later be reduced to the amino group or, .ef . 3507 ne0045 in the case of the cyano group, also be converted into the formamidino group.
Compounds of the general formula IIIb H COOH
R1 i°'~ , (IIIb) N
can be obtained analogously if, instead of isocyanatoalkanecarboxylic acid esters, the isocyanates of the aminobenzoic acid esters are employed.
Compounds of the general formula IIIc H
-~
X1 ~C~ (IIIc) N-'Y-0 H
R 2-N---~
can be obtained by reaction of hydantoins of the general formula VIII
H
H°C--~~
N-Y-OH (VIII) R 2-N--~
with aldehydes of the general formula IX
H° (Ix) xi analogously to Granacher and Landolt, Helv. Chim. Acta 10 (1927) 808.
Otherwise, hydantoins of the general formula Xa 2~~~~'~'~3 .;ef . 3507 ne0045 R " ~ ~N-C H 2-C-R 1 1 HN---~ (Xa) in which Rl° denotes any desired amino acid side chain and Rli denotes an amide, an amino acid residue or a peptide residue, very commonly result by basic treatment of alkoxycarbonyl 5 peptides or aralkoxycarbonyl peptides of the general formula X
R12-0-CO-NH-CHR1°-CO-NH-CHZ-CO-R11 ( X ) in which Rl° and Rl' are defined as indicated above and R12 denotes benzyl or tert-butyl (J. S. Fruton and M. Bergmann, J. Biol.
Chem. 145 (1942) 253 - 265; C. A. Dekker, S. P. Taylor, jr. and 10 J. S. Fruton, J. Biol. Chem. 180 (1949) 155 - 173; M. E. Cox, H.
G. Carg, J. Hollowood, J. M. Hugo, P. M. Scopes and G. T. Young, J. Chem. Soc. (1965) 6806 - 6813; W. Voelter and A. Altenburg, Liebigs Ann. Chem. (1983) 1641 - 1655; B. Schwenzer, E. Weber and G. Losse, J. Prakt. Chem. 327 (1985) 479 - 486). In this case, however, the N-terminal amino acid racemises and the hydantoin hydrolyses to the urea derivative HOCO-CHR1°-NH-CO-NH-CHZ-CO-Rli (W. Voelter and A. Altenburg, Liebigs Ann. Chem. (1983) 1641 - 1655).
In comparison, a mild method is cyclisation to give the hydantoins from compounds of the general formula X by treatment with tetrabutylammonium fluoride in tetrahydrofuran under reflux (J. Pleas, J. Org. Chem. 39 (1974) 2644 - 2646).
A further possibility of a mild cyclisation is trimethylsilylation of the peptide bond between the N-terminal amino acid and the following glycine using biatrimethylsilyltrifluoroacetamide in acetonitrile (4 hours under reflux) (J. S. Davies, R. K. Merritt and R. C. Treadgold, J. Chem. Soc. Perkin Trans. I (1982) 2939 - 2947).
The guanylation of the amino function can be carried out using the following reagents:
1. O-Methylisothiourea (S. Weiss and H. Krommer, Chemiker Zeitung 98 (1974) 617 - 618), Ref.3507 ~e0045 2. S-Methylisothiourea (R. F. Borne, M. L. Forrester and I. W.
Waters, J. Med. Chem. 20 (1977) 771 - 776), 3. Nitro-S-methylisothiourea (L. S. Hafner and R. E. Evans, J.
Org. Chem. 24 (1959) 1157), 4. Formamidinosulphonic acid (K. Kim, Y.-T. Lin and H. S. Mosher, Tetrah. Lett. 29 (1988) 3183 - 3186), 5. 3,5-Dimethyl-1-pyrazolylformamidinium nitrate (F. L. Scott, D.
G. O~Donovan and J. Reilly, J. Amer. Chem. Soc. 75 (1953) 4053 - 4054).
Formamidines can be prepared from the corresponding cyano compounds by addition of alcohols (for example methanol or ethanol) in acidic anhydrous medium (for example dioxane, methanol or ethanol) and subsequent treatment with ammonia in alcohols (for example isopropanol, methanol or ethanol) (G.
Wagner, P. Richter and Ch. Garbs, Pharmazie 29 (1974) 12 - 55). A
further method of preparing formamidines is the addition of H2S to the cyano group, followed by a methylation of the resulting thioamide and subsequent reaction with ammonia (GDR Patent No.
235,866).
The starting peptides of the general formula IV are as a rule synthesised stepwise from the C-terminal end. Formation of peptide bonds can be carried out using the known coupling methods of peptide chemistry.
The compounds of the general formula I and their physiologically tolerable salts can be administered as medicines per se on their own, in mixtures with one another or in the form of pharmaceutical preparations which permit enteral or parenteral use and which contain, as active constituent, an effective dose of at least one compound of the general formula I or of a salt thereof, in addition to customary pharmaceutically innocuous excipients and additives. The preparations normally contain about 0.5 to 90$ by weight of the therapeutically active compound.
The medicines can be administered orally, for example in the form of pills, tablets, coated tablets, sugar-coated tablets, granules, hard and soft gelatine capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration can also be carried out, however, rectally, for example in the form 20~~~'~'~3 ;ef . 3507 ne0045 of suppositories, or parenterally, for example in the form of injection solutions or microcapsules, percutaneously, for example in the form of ointments or tinctures or nasally, for example in the form of nasal sprays.
The pharmaceutical preparations can be prepared in a manner known per se, pharmaceutically inert inorganic or organic excipients being used. For the preparation of pills, tablets, coated tablets and hard gelatine capsules, lactose, maize starch or derivatives thereof, talc, stearic acid or its salts, etc., for example, can be used. Excipients for soft gelatine capsules and suppositories are, for example, fats, waxes, semi-solid and liquid polyols, natural or hardened oils, etc. Suitable excipients for the preparation of solutions and syrups are, for example, water, sucrose, dextrose, glucose, polyols etc. Suitable excipients for the preparation of injection solutions are water, alcohols, glycerol, polyols or vegetable oils, etc. Suitable excipients for microcapsules or implants are, for example, copolymers of glycolic acid and lactic acid.
Apart from the active compounds and excipients, the pharmaceutical preparations can additionally contain additives such as, for example, fillers, extenders, disintegrants, binders, lubricants, wetting agents, stabilisers, emulsifiers, pre-servatives, sweeteners, colorants, flavourings or aromatisers, thickeners, diluents, buffer substances, and also solvents or solubilisers or agents for achieving a depot effect as well as salts for changing the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the general formula I or their physiologically tolerable salts and additionally one or more other therapeutically active substances.
Other therapeutically active substances of this type are, for example, agents promoting the circulation, such as dihydroergocristine, nicergoline, buphenine, nicotinic acid and its esters, pyridylcarbinol, bencyclan, cinnarizine, naftidrofuryl, raubasine and vincamine; positively inotropic compounds, such as digoxin, acetyldigoxin, metildigoxin and lanthanoglycosides; coronary dilators, such as carbochromen;
dipyramidol, nifedipine and perhexiline; antianginal compounds, Ref . 3507 2 ~ ~ ~~ "~ "~ 3 ze0045 such as isosorbide dinitrate, isosorbide mononitrate, glycerol nitrate, molsidomine and verapamil; ,9-blockers, such as propranolol, oxprenolol, atenolol, metoprolol and penbutolol. The compounds may moreover be combined with other nootropic substances, such as, for example, piracetam, or CNS-active substances, such as pirlindol, sulpiride, etc.
The dose can vary within wide limits and is to be adapted to the individual conditions in each individual case. In general, in the case of oral administration a daily dose of about 0.1 to 1 mg/kg, preferably 0.3 to 0.5 mg/kg, of body weight is appropriate to achieve effective results, in the case of intravenous administration the daily dose is in general about 0.01 to 0.3 mg/kg, preferably 0.05 to 0.1 mg/kg, of body weight.
The daily dose is normally divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. In some cases, depending on individual behaviour, it may be necessary to deviate upwards or downwards from the given daily dose. Pharmaceutical preparations normally contain 0.2 to 50 mg, preferably 0.5 to 10 mg, of active compound of the general formula I or one of its physiologically tolerable salts per dose.
The compounds of the formula I according to the invention have the ability to inhibit cell-cell adhesion which is due to the interaction of Arg-Gly-Asp-containing proteins, such as fibronectin, fibrinogen or the von Willebrand factor, with the so-called integrins. Integrins are transmembrane glycoproteins, receptors for Arg-Gly-Asp-containing cell matrix glycoproteins (E. Ruoslahti and M. D. Pierschbacher, Science 238 (1987) 491 - 497; D. R. Phillips, I. F. Charo, L. V. Parise and L. A.
Fitzgerald, Blood 71 (1988) 831 - 843). They additionally inhibit the binding of other adhesive proteins, such as vitronectin, collagen and laminin, to the corresponding receptors on the surface of various types of cell.
The compounds of the general formula I according to the invention inhibit platelet aggregation, the metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
The hydantoin derivatives of the general formula I are Ref.3507 ne0045 used acutely in risk of thrombosis and chronically in the prevention of arteriosclerosis and thrombosis, for example in the therapy and prophylaxis of arterial vascular diseases, such as in acute myocardial infarct, secondary prevention of myocardial infarct, reocclusion prophylaxis after lysis and dilatation (PCTA), unstable angina pectoris, transitory ischaemic attacks, strokes, coronary bypass operation including bypass reocclusion prophylaxis, pulmonary embolism, peripheral arterial occlusive disease, dissecting aneurysm; in the therapy of venous and microcirculatory vascular disorders, such as deep vein thrombosis, disseminated intravascular clotting, post-operative and post-partum trauma, surgical or infectious shock, septicaemia or in hyperactive platelet diseases, thrombotic thrombocytopenic purpura, preeclampsia, premenstrual syndrome, dialysis or extracorporeal circulation; a further use is during cancer operations and also prophylactically in cancer. Osteoporosis can also be prevented by inhibition of osteoclast binding to the bone surface.
The compounds are tested in particular for their inhibitory action in blood platelet aggregation and the adhesion of fibrinogen to blood platelets. Gel-filtered blood platelets from human donor blood are used, which are activated with ADP or thrombin.
Examples:
The products were identified by means of mass spectra and/or NMR spectra.
Example l:
(5-(S)-(3-Guanidinopropyl)-2,4-dioxoinidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (4-aminobutyl) amide acetate la: Z-Phe-NH-(CHZ),-NH-Boc 5.98 g (20 mmol) of N-benzyloxycarbonyl-L-phenylalanine and 4.49 g (20 mmol) of 4-(tert-butoxycarbonylamino)butylamine hydrochloride are dissolved in 100 ml of dimethylformamide and cooled to 0°C in an ice-bath. After addition of 2.7 g (20 mmol) of hydroxybenzotriazole, 4.4 g (20 mmol) of DCCI and 2.54 ml Ref . 3507 ne0045 (20 mmol).of N-ethylmorpholine, the reaction is stirred overnight. The precipitated urea is filtered off with suction and the solution is evaporated in a high vacuum. The residue is taken up in 200 ml of ethyl acetate and the organic phase is extracted with water, sodium hydrogen carbonate solution and potassium hydrogen sulphate solution and dried over magnesium sulphate.
After filtration and concentration, 8.2 g (87%) of amorphous product are obtained.
1b: H-Phe-NH-(CHZ)~-NH-Hoc hydrochloride 8.2 g (1?.5 mmol) of Z-Phe-NH-(CH2),-NH-Hoc are dissolved in 300 ml of methanol and treated with 1.5 g of Pd/C. Hydrogen is then introduced and the pH is maintained at 4 by addition of methanolic hydrochloric acid. After completion of the reaction, the mixture is filtered and the filtrate is evaporated. After triturating with ether, 6.5 g (100%) of amorphous product are obtained.
lc: H-L-Aspartyl(OtHu)-L-phenylalanine-NH-(CHZ),-NH-Hoc hydrochloride 5.6 g (1?.4 mmol) of Z-Asp(OtBu)-OH and 6.5 g (17.5 mmol) of H-Phe-NH-(CHZ),-NH-Boc hydrochloride are dissolved in 100 ml of dimethylformamide. After addition of 2.3 g (17 mmol) of hydroxybenzotriazole, 4.4 g (21.3 mmol) of nCCI and 2.2 ml (17.3 mmol) of N-ethylmorpholine, the reaction is stirred overnight. After completion of the reaction, the mixture is concentrated in vacuo. The residue is taken up in ethyl acetate and the organic phase is extracted with water and sodium hydrogen carbonate solution and then dried using magnesium sulphate. After filtration and concentration, 9.7 g of crude product are obtained, which is purified by chromatography.
The combined fractions are hydrogenated as described in 1b. The residue from the hydrogenation is dissolved in 50 ml of ethyl acetate and precipitated using petroleum ether. 4.9 g are obtained.
FAB-MS 507.3 (M+H)+
1d: 5-(S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl L-aspartyl(OtBu)-L-phenylalanine (4-Hoc-aminobutyl) amide 977 mg (1.8 mmol) of H-L-aspartyl(OtBu)-L-phenylalanine-Ref.3507 ne004 U .~ !5 NH-(CHZ),-N-H-Boc hydrochloride and 500 mg of 5-(S)-(3-guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetic acid are dissolved in 5 ml of dimethylformamide. 243 mg (1.8 mmol) of hydroxybenzotriazole and 412 mg (2 mmol) of DCCI are added to the solution and it is stirred overnight. After completion of the reaction, the solution is concentrated and the residue is chromatographed on silica gel without further treatment (eluent:
CHZC12, CH30H, acetic acid, water = 85:10:2.5:2.5). 1.03 g (76%) of product are isolated.
FAB-MS 746.6 (M+H)'' 1e: (5-(S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (4-aminobutyl) amide acetate 1 g (1.38 mmol) of 5-(S)-(3-guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl(OtBu)-L-phenylalanine 4-Boc-aminobutyl amide are stirred at room temperature for 1 hour in 15 ml of 90% strength aqueous trifluoroacetic acid. The solution is then concentrated, the residue is taken up in water and the solution is treated with ion exchanger IRA-93 until a pH of 4 is obtained. The solution is freeze-dried and the residue (880 mg) is chromatographed on Sephadex LH20 using 1 M acetic acid. After concentration and freeze-drying, 735 mg (90%) of product are obtained.
FAB-MS 590.1 (M+H)'"
Example 2:
(5-(S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl L-aspartyl-L-phenylalanine (6-aminohexyl) amide acetate This compound was prepared analogously to the method described in Example 1.
FAB-MS 618.1 (M+H)+
Example 3:
(5-(S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (8-aminooctyl) amide acetate This compound was prepared analogously to the method describd in Example 1.
FAB-MS 646 (M+H)"
2 (~ ~ ~ '~ '~ 3 .tef . 3507 ne0045 Example 4:
(5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (4-aminobutyl) amide acetate This compound was prepared analogously to the method described in Example 1.
FAB-MS 623 (M+H)+
Example 5:
(5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (6-aminohexyl) amide acetate This compound was prepared analogously to the method described in Example 1.
FAB-MS 651 (M+H)r Example 6:
(5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-phenylalanine (8-aminooctyl) amide acetate This compound was prepared analogously to the method described in Example 1.
FAB-MS 679 (M+H)'' Example 7:
(5-(R,S)-(4-Formamidino-benzyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-lysine (4-aminobutyl) amide 7a: H-Aspartyl(OtHu)-L-lysine(Hoc)-NH-(CHZ),-NH-Hoc hydrochloride 1.17 ml of N-ethylmorpholine and 1.98 g of DCCI are added at 0°C to a solution of 5.3 g of H-Lys(Boc)-NH-(CHZ),-NH-Boc tosylate, 2.91 g of Z-Asp(OtBu)-OH and 1.21 g of hydroxybenzotriazole in 20 ml of dimethylformamide. The mixture is stirred at 0°C for 1 hour and at room temperature for 4 hours and allowed to stand overnight at room temperature. The precipitate is filtered off with suction and the filtrate is concentrated in vacuo. The residue is partitioned between ethyl acetate and water. The organic phase is extracted with sodium hydrogen carbonate solution, potassium hydrogen sulphate solution and water and dried over sodium sulphate and concentrated. The z I t1 I II
. . CA 02094773 2002-11-22 residue is triturated with ether and filtered off with suction.
The product obtained (5.2 g) is dissolved in 150 ml of methaaol and catalytically hydrogenated over Pd/carbon at pH 4.5 using methanolic hydrochloric acid in as autoburette. After reaction waa complete, the catalyst was filtered off with suction aad the filtrate was concentrated.
Yield: 4.12 g of amorphous substance a)az' _ +3.9° (c = 1, methanol) 7b: (5-(R,S)-(4-Fotmamidiaobeazyl)-2,4-diouo~midazoh.din-3-yl)acetyl-L-aspartpl(OtBn)-L-lpsiae(Hoc) (4-Hoc-~ei.,aobntyl) amide 1.I g of DCCI are added at 0°C to a suspension of 1.54 g of (5-(R,S)-(4-fo~~m~dinobenzyl)-2,4-dioxoimidazolidin-3-yl) acetic acid, 3.1 g of H-aspartyl(OtBu)-L-lysine(Boc)-NH-(CHZ)"-NH-Boc hydrochloride and 675 mg of hydroxybenzotriazole in 20 ml of dimethylfo~~~~~de. The mixture is stirred at 0°C for 1 hour and at room temperature for 4 hours and allowed to stand overnight at room temperature. The precipitate is filtered off with suction and the filtrate is conceatrated in vacuo. For purification, the substance is chromatographed on silica gel in methylene chloride/methanol/water/acetic acid = 8.5:1.5:0.2:0.Z.
Yield: 3.26 g of amorphous substance a ) Dzo = -2 8 7 0 ( C ~ 1, methanol ) 7c: (5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoimidazolidia-3-yl)acetyl-L-aspartyl-L-lysine (4-aminobatyl) amide diacetate 3.15 g of (5-(R, S)-(4-fo~~m~dinobenzylj-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl(Oteu)-L-lysine(Boc) (4-Boc-aminobutyl) amide are dissolved in 30 ml of 90% strength aqueous trifluoroacetir acid. After one houz at room temperature-the mixture is concentrated in vacuo and the residue is partitioned between water and diethyl ether. The aqueous phase °
(30 ml) is chroiaatographed on 50 ml of Amberlite iA 93 (acetate form) and water as the eluent. The eluate is lyophilised and gives 2.42 g of substance. For purification, the substance is chramatographed on Sephadex L&20 (200 x 4 cm) in a mixture of acetic acid, n-butanol and water. The fractions containing pure substance are concentrated, dissolved in water and freeze-dried *Trade-mark r Ref.3507 ne0045 Yield 2.27 g a)p2' _ -35.2° (c = 1, water) Example 8:
(5-(R,S)-(3-Guanidinopropyl)-2,4-dioxoimidazolidin-3-yl)acetyl-L-aspartyl-L-valine (4-aminobutyl) amide This compound was prepared analogously to the method described in Example 1.
FAB-MS 541 (M+H)'' Example 9:
(5-(R,S)-(4-Formamidinobenzyl)-2,4-dioxoiaidazolidin-3-yl)acetyl-L-aspartyl-L-phenylglycine (4-aminobutyl) amide This compound was prepared analogously to the method described in Example 1.
FAB-MS 608 (M+H)'' Example A:
Emulsions containing 3 mg of active compound per 5 ml can be prepared according to the following recipe:
Active compound 0.06 g Neutral oil q.s.
sodium carboxymethylcellulose 0.6 g Polyoxyethylene stearate q.s.
Pure glycerol 0.6 to 2 g Aromatics q.s.
Water (demineralised or distilled) to 100 ml ~Ref.3507 ne0045 Example B:
Tablets can be prepared according to the following formulation:
Active compound 2 mg Lactose 60 mg Maize starch 30 mg Soluble starch 4 mg Magnesium stearate 4 mg 100 mg 8xample C:
The following composition is suitable for the preparation of soft gelatine capsules containing 5 mg of active compound per capsule:
Active compound 5 mg Mixture of triglycerides from coconut oil 150 mg Capsule contents . 155 mg Example D:
The following formulation is suitable for the preparation of sugar-coated teblets:
Active compound 3 mg Maize starch 100 mg Lactose 55 mg Sec. calcium phosphate 30 mg Soluble starch 3 mg Magnesium stearate 5 mg Colloidal silica 4 mg 200 mg Example E:
Sugar-coated tablets containing an active compound according to the invention and another therapeutically active substance:
Ref . 3507 ne0045 Active compound 6 mg Propanolol 40 mg Lactose 90 mg Maize starch 90 mg Sec. calcium phosphate 34 mg Soluble starch 3 mg Magnesium stearate 3 mg Colloidal silica 4 mg 270 mg Example F:
Sugar-coated tablets containing an active compound according to the invention and another therapeutically active substance:
Active compound 5 mg Pirlindol 5 mg Lactose 60 mg Maize starch 90 mg Sec. calcium phosphate 30 mg Soluble starch 3 mg Magnesium stearate 3 mg Colloidal silica 4 mg 200 mg Example G:
Capsules containing an active compound according to the invention and another therapeutically active substance:
Active compound 5 mg Nicergoline 5 mg Maize starch 185 mg 195 mg Example H: ' Injection solutions containing 1 mg of active compound per ml can be prepared according to the following recipe:
~ef.3507 ne0045 Active compound 1.0 mg Polyethylene glycol 400 0.3 mg Sodium chloride 2.7 mg Water for injection purposes to 1 ml Pharmacological data:
The inhibition of the binding of fibrinogen to its receptor (glycoprotein IIb/IIIa) by the compounds according to the invention is tested on intact, gel-filtered human platelets.
The R~ value of the inhibition of binding of '2sI-fibrinogen after stimulation with ADP (10 pM) is given.
References:
J.S. Bennett and G. Vilaire, J. Clin. Invest. 64 (1979), E. Kornecki et al., J. Biol. Chem. 256 (1981), 5695-5701 G.A. Marguerie et al., J. Biol. Chem. 254 (1979), 5357-5363 G.A. Marguerie et al., J. Biol. Chem. 255 (1980), 154-161 8xample Rs (~M), ADP-stimulated 1 2.50 2 2.44 3 3.21 4 0.32 7 0.17 As a functional test, the inhibition of aggregation of gel-filtered human platelets by the compounds according to the invention is measured after ADP or thrombin stimulation. The ICso value of the inhibition is given.
Reference:
G.A. Marguerie et al., J. Biol. Chem. 254 (1979), 5357-5363 Ref.3507 ne0045 Bxample ICS ~~~il.
ADP-stimulated Thrombin-stimulated 1 1.5 2.0 2 3.0 3.5 3 5.0 3.0 4 0.45 1.0 7 0.25 0.6
Claims (8)
1. A compound of the general formula I
or a physiologically tolerable salt thereof, in which Y denotes -(CH2)m-CO-, where m represents an integer from 1 to 4, or R1 denotes -(CH2)n-NH-X, where n represents an integer from 1 to 6, -(CH2)p-C6H4-NH-X, -(CH2)p-C6H4-C(=NH)-NH2 or (CH2)p-C6H4-CH2-NH-X, where p in each case represents 1 or 2, but also where instead of can be present;
X1 denotes -NHX, -CH2NHX or -C(=NH)-NH2;
X denotes hydrogen, (C1-C6)-alkyl or a radical of the formula II
where R' and R'' independently of one another represent hydrogen or (C1-C6)-alkyl;
R2 denotes hydrogen or (C1-C6)-alkyl;
R3 denotes hydrogen or phenyl;
R4 denotes -COOR5, CO-N(CH3)-R5 or -CO-NH-R5;
R5 denotes (C1-C28)-alkyl which is substituted a) by mono- or di-(C1-C18)-alkylaminocarbonyl, amino-(C2-C14)-alkylaminocarbonyl, amino-(C1-C3)-alkylphenyl-(C1-C3)-alkylaminocarbonyl, (C1-C18)-alkylcarbonylamino-(C1-C3)-alkyl-phenyl-(C1-C3)-alkylaminocarbonyl or (C1-C18)-alkylcarbonyl-amino-(C2-C14)-alkylaminocarbonyl, where the alkyl radicals for their part can be substituted by hydroxyl, amino, mercapto, (C1-C18)-alkoxy, halogen, nitro, trifluoromethyl, (C6-C14) aryl or (C6-C14)-aryl-(C1-C8)-alkyl and which b) is optionally additionally monosubstituted or polysubstituted by identical or different radicals from the series consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, amino, mercapto, (C1-C18)-alkoxy, (C1-C18)-alkoxycarbonyl, (C6-C14)-aryl-(C1-C3)alkoxycarbonyl, (C3-C8)-cycloalkyl, halogen, nitro, trifluoromethyl and a radical R6;
R6 denotes (C6-C14)-aryl, (C6-C14)-aryl-(C1-C8)-alkyl, a monocyclic or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which as the heteroelement can contain one, two or three identical or different nitrogen, oxygen or sulphur atoms, or denotes a radical R7, where the aryl radical and, independently thereof, the heterocyclic radical can be optionally monosubstituted or polysubstituted by identical or different radicals from the series consisting of (C1-C18)-alkyl, (C1-C18)-alkoxy, halogen, nitro and trifluoromethyl;
R7 denotes -NR8R9, -OR8, -SR8, an amino acid side chain, a natural or unnatural amino acid residue, imino acid residue, optionally N-(C1-C8)-alkylated or (C6-C14)-aryl-(C1-C8)-alkylated azaamino acid residue or dipeptide residue, in which the peptide bond can be reduced to NH-CH2, and also their esters and amides, where free functional groups can optionally be substituted by hydrogen or hydroxymethyl or be protected by protective groups selected from the group consisting of Aloc, Pyoc, Fmoc, Tcboc, Z, Boc, Ddz, Bpoc, Adoc, Msc, Moc, Z(NO2), Z(Hal n), Bobz, Iboc, Adpoc,Mboc, Acm, tert-butyl, OBzl, ONbzl,OMbzl, Bzl, Mob, Pic,and Trt, or denotes a radical -COR7', in which R7' is defined as R7;
R8 denotes hydrogen, (C2-C18)-alkyl, (C6-C14)-aryl-(C1-C8)-alkyl, (C1-C18)-alkylcarbonyl, (C1-C18)-alkoxycarbonyl, (C6-C14)-arylcarbonyl, (C6-C14)-aryl-(C1-C8)-alkylcarbonyl, (C6-C14)-aryl-(C1-C18)-alkoxycarbonyl, where the alkyl groups can optionally be substituted by an amino group, a natural or unnatural amino acid residue, imino acid residue, optionally N-(C1-C8)-alkylated or (C6-C14)-aryl-(C1-C8)-alkylated azaamino acid residue or a dipeptide residue, in which the peptide bond can be reduced to NH-CH2: and R9 denotes hydrogen, (C1-C18)-alkyl, (C6-C14)-aryl or (C6-C14)-aryl-(C1-C8)-alkyl.
or a physiologically tolerable salt thereof, in which Y denotes -(CH2)m-CO-, where m represents an integer from 1 to 4, or R1 denotes -(CH2)n-NH-X, where n represents an integer from 1 to 6, -(CH2)p-C6H4-NH-X, -(CH2)p-C6H4-C(=NH)-NH2 or (CH2)p-C6H4-CH2-NH-X, where p in each case represents 1 or 2, but also where instead of can be present;
X1 denotes -NHX, -CH2NHX or -C(=NH)-NH2;
X denotes hydrogen, (C1-C6)-alkyl or a radical of the formula II
where R' and R'' independently of one another represent hydrogen or (C1-C6)-alkyl;
R2 denotes hydrogen or (C1-C6)-alkyl;
R3 denotes hydrogen or phenyl;
R4 denotes -COOR5, CO-N(CH3)-R5 or -CO-NH-R5;
R5 denotes (C1-C28)-alkyl which is substituted a) by mono- or di-(C1-C18)-alkylaminocarbonyl, amino-(C2-C14)-alkylaminocarbonyl, amino-(C1-C3)-alkylphenyl-(C1-C3)-alkylaminocarbonyl, (C1-C18)-alkylcarbonylamino-(C1-C3)-alkyl-phenyl-(C1-C3)-alkylaminocarbonyl or (C1-C18)-alkylcarbonyl-amino-(C2-C14)-alkylaminocarbonyl, where the alkyl radicals for their part can be substituted by hydroxyl, amino, mercapto, (C1-C18)-alkoxy, halogen, nitro, trifluoromethyl, (C6-C14) aryl or (C6-C14)-aryl-(C1-C8)-alkyl and which b) is optionally additionally monosubstituted or polysubstituted by identical or different radicals from the series consisting of hydroxyl, hydroxycarbonyl, aminocarbonyl, amino, mercapto, (C1-C18)-alkoxy, (C1-C18)-alkoxycarbonyl, (C6-C14)-aryl-(C1-C3)alkoxycarbonyl, (C3-C8)-cycloalkyl, halogen, nitro, trifluoromethyl and a radical R6;
R6 denotes (C6-C14)-aryl, (C6-C14)-aryl-(C1-C8)-alkyl, a monocyclic or bicyclic 5- to 12-membered heterocyclic ring which can be aromatic, partially hydrogenated or completely hydrogenated and which as the heteroelement can contain one, two or three identical or different nitrogen, oxygen or sulphur atoms, or denotes a radical R7, where the aryl radical and, independently thereof, the heterocyclic radical can be optionally monosubstituted or polysubstituted by identical or different radicals from the series consisting of (C1-C18)-alkyl, (C1-C18)-alkoxy, halogen, nitro and trifluoromethyl;
R7 denotes -NR8R9, -OR8, -SR8, an amino acid side chain, a natural or unnatural amino acid residue, imino acid residue, optionally N-(C1-C8)-alkylated or (C6-C14)-aryl-(C1-C8)-alkylated azaamino acid residue or dipeptide residue, in which the peptide bond can be reduced to NH-CH2, and also their esters and amides, where free functional groups can optionally be substituted by hydrogen or hydroxymethyl or be protected by protective groups selected from the group consisting of Aloc, Pyoc, Fmoc, Tcboc, Z, Boc, Ddz, Bpoc, Adoc, Msc, Moc, Z(NO2), Z(Hal n), Bobz, Iboc, Adpoc,Mboc, Acm, tert-butyl, OBzl, ONbzl,OMbzl, Bzl, Mob, Pic,and Trt, or denotes a radical -COR7', in which R7' is defined as R7;
R8 denotes hydrogen, (C2-C18)-alkyl, (C6-C14)-aryl-(C1-C8)-alkyl, (C1-C18)-alkylcarbonyl, (C1-C18)-alkoxycarbonyl, (C6-C14)-arylcarbonyl, (C6-C14)-aryl-(C1-C8)-alkylcarbonyl, (C6-C14)-aryl-(C1-C18)-alkoxycarbonyl, where the alkyl groups can optionally be substituted by an amino group, a natural or unnatural amino acid residue, imino acid residue, optionally N-(C1-C8)-alkylated or (C6-C14)-aryl-(C1-C8)-alkylated azaamino acid residue or a dipeptide residue, in which the peptide bond can be reduced to NH-CH2: and R9 denotes hydrogen, (C1-C18)-alkyl, (C6-C14)-aryl or (C6-C14)-aryl-(C1-C8)-alkyl.
2. A compound according to claim 1, wherein in general formula I
Y denotes -(CH2)m-CO-, where m represents 1 or 2, or R1 denotes -CH2-C6H4-NH-C(=NH)-NH2; -CH2-C6H4-C(=NH)-NH2 or -CH2-C6H4-CH2-NH2;
R2 denotes hydrogen or methyl;
R3 denotes hydrogen; and R4 denotes -CO-NH-R5, where -NH-R5 represents an w-amino-(C2-C8)-alkyl amide of an .alpha.-amino acid residue.
Y denotes -(CH2)m-CO-, where m represents 1 or 2, or R1 denotes -CH2-C6H4-NH-C(=NH)-NH2; -CH2-C6H4-C(=NH)-NH2 or -CH2-C6H4-CH2-NH2;
R2 denotes hydrogen or methyl;
R3 denotes hydrogen; and R4 denotes -CO-NH-R5, where -NH-R5 represents an w-amino-(C2-C8)-alkyl amide of an .alpha.-amino acid residue.
3. A compound according to claim 2, wherein -NH-R5 represents the 4-aminobutyl amide of the valine, lysine, phenyl-alanine or phenylglycine residue.
4. A process for the preparation of a compound of formula I according to claim 1, 2 or 3, which process comprises condens-ing a compound of the general formula III
with a compound of the general formula IV
wherein the radicals R1 to R4 and Y are as defined in claim 1.
with a compound of the general formula IV
wherein the radicals R1 to R4 and Y are as defined in claim 1.
5. A pharmaceutical composition comprising an effective amount of a compound of the formula I according to claim 1, 2 or 3, or a physiologically tolerable salt thereof, in admixture with a pharmaceutically acceptable diluent or carrier.
6. Use of a compound of the general formula I
according to claim 1, 2 or 3 or a physiologically tolerable salt thereof or a pharmaceutical composition according to claim 5, as an inhibitor of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
according to claim 1, 2 or 3 or a physiologically tolerable salt thereof or a pharmaceutical composition according to claim 5, as an inhibitor of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
7. A method of making a medicament, which method comprises incorporating a compound of formula I according to claim 1, 2 or 3, or a physiologically tolerable salt thereof or a pharmaceutical composition according to claim 5 as active ingredient in the medicament.
8. A commercial package containing as active pharmaceutical ingredient a compound of the formula I
according to claim l, 2 or 3, or a physiologically tolerable salt thereof or a pharmaceutical composition according to claim 5, together with instructions for the use thereof as an inhibitor of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
according to claim l, 2 or 3, or a physiologically tolerable salt thereof or a pharmaceutical composition according to claim 5, together with instructions for the use thereof as an inhibitor of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4213634.2 | 1992-04-24 | ||
| DE4213634A DE4213634A1 (en) | 1992-04-24 | 1992-04-24 | 2,4-dioxo-imidazolidin-derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2094773A1 CA2094773A1 (en) | 1993-10-25 |
| CA2094773C true CA2094773C (en) | 2003-11-04 |
Family
ID=6457462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002094773A Expired - Lifetime CA2094773C (en) | 1992-04-24 | 1993-04-23 | 2,4-dioxoimidazolidine derivatives |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5397796A (en) |
| EP (1) | EP0566919B1 (en) |
| JP (1) | JP3793242B2 (en) |
| AT (1) | ATE236886T1 (en) |
| AU (1) | AU665068B2 (en) |
| CA (1) | CA2094773C (en) |
| CZ (1) | CZ287885B6 (en) |
| DE (2) | DE4213634A1 (en) |
| ES (1) | ES2194842T3 (en) |
| IL (1) | IL105511A (en) |
| SK (1) | SK39293A3 (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4224414A1 (en) * | 1992-07-24 | 1994-01-27 | Cassella Ag | Phenylimidazolidine derivatives, their preparation and their use |
| DE4228717A1 (en) * | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidine derivatives |
| DE4308034A1 (en) * | 1993-03-13 | 1994-09-15 | Cassella Ag | New heterocycles, their preparation and their use |
| PT825184E (en) * | 1993-03-29 | 2001-11-30 | Astrazeneca Ab | HETEROCYCLIC DERIVATIVES AS PLATELET INHIBITORS |
| US5750754A (en) * | 1993-03-29 | 1998-05-12 | Zeneca Limited | Heterocyclic compounds |
| US5753659A (en) * | 1993-03-29 | 1998-05-19 | Zeneca Limited | Heterocyclic compouds |
| US5652242A (en) * | 1993-03-29 | 1997-07-29 | Zeneca Limited | Heterocyclic derivatives |
| ZW4194A1 (en) * | 1993-03-29 | 1994-12-21 | Zeneca Ltd | Heterocyclic compounds |
| US5463011A (en) * | 1993-06-28 | 1995-10-31 | Zeneca Limited | Acid derivatives |
| GB9313268D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Chemical compounds |
| GB9313285D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Acid derivatives |
| DE4427979A1 (en) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituted 5-ring heterocycles, their preparation and their use |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| ZA963391B (en) * | 1995-05-24 | 1997-10-29 | Du Pont Merck Pharma | Isoxazoline fibrinogen receptor antagonists. |
| DE59706273D1 (en) | 1996-03-20 | 2002-03-21 | Hoechst Ag | Bone resorption inhibitors and vitronectin receptor antagonists |
| DE19622489A1 (en) | 1996-06-05 | 1997-12-11 | Hoechst Ag | Salts of 3- (2- (4- (4- (aminoimino-methyl) -phenyl) -4-methyl-2,5-dioxo-imidazolidin-1-yl) -acetylamino) -3-phenyl-propionic acid- ethyl esters |
| DE19629817A1 (en) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | New imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
| DE19629816A1 (en) * | 1996-07-24 | 1998-01-29 | Hoechst Ag | New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists |
| DE19647380A1 (en) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-ring heterocycles as inhibitors of leukocyte adhesion and VLA-4 antagonists |
| DE19741235A1 (en) * | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| DE19741873A1 (en) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | New 5-ring heterocycles, their preparation, their use and pharmaceutical preparations containing them |
| DE19751251A1 (en) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituted imidazolidine derivatives, their manufacture, their use and pharmaceutical preparations containing them |
| DE19821483A1 (en) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders |
| DE19922462A1 (en) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | New phenylureidobenzyl-substituted spiro-imidazolidinedione derivatives, are inhibitors of leukocyte adhesion or migration or VLA-4 receptors, useful e.g. for treating inflammatory or allergic disease |
| DE10111877A1 (en) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| DE10137595A1 (en) * | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | New 3-alkylaminoalkyl-imdazolidin-4-one derivatives, are VLA-4 receptor and leukocyte adhesion and/or migration inhibitors, useful e.g. for treating inflammatory, allergic, autoimmune or cardiovascular disease |
| EP1620092A4 (en) * | 2003-05-07 | 2008-04-16 | Cytokinetics Inc | Compounds, compositions, and methods |
| US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
| US20060045902A1 (en) * | 2004-09-01 | 2006-03-02 | Serbousek Jon C | Polymeric wrap for in vivo delivery of osteoinductive formulations |
| US20060057184A1 (en) * | 2004-09-16 | 2006-03-16 | Nycz Jeffrey H | Process to treat avascular necrosis (AVN) with osteoinductive materials |
| US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
| US9119901B2 (en) * | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
| US20070077267A1 (en) * | 2005-10-03 | 2007-04-05 | Sdgi Holdings, Inc. | Bioactive composite implants |
| US20070179615A1 (en) * | 2006-01-31 | 2007-08-02 | Sdgi Holdings, Inc. | Intervertebral prosthetic disc |
| US20070179618A1 (en) * | 2006-01-31 | 2007-08-02 | Sdgi Holdings, Inc. | Intervertebral prosthetic disc |
| US20070280986A1 (en) * | 2006-06-01 | 2007-12-06 | Carlos Gil | Intra-operative coating of implants |
| US8133553B2 (en) * | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
| US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
| US8608049B2 (en) * | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
| US20110230973A1 (en) * | 2007-10-10 | 2011-09-22 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
| US20090187256A1 (en) * | 2008-01-21 | 2009-07-23 | Zimmer, Inc. | Method for forming an integral porous region in a cast implant |
| US20090192609A1 (en) * | 2008-01-29 | 2009-07-30 | Zimmer, Inc. | Implant device for use in an implant system |
| US20090198286A1 (en) * | 2008-02-05 | 2009-08-06 | Zimmer, Inc. | Bone fracture fixation system |
| US11020160B2 (en) | 2016-03-21 | 2021-06-01 | Warsaw Orthopedic, Inc. | Surgical injection system and method |
| US10709814B2 (en) | 2016-04-22 | 2020-07-14 | Warsaw Orthopedic, Inc. | Osteoimplant comprising an insoluble fibrous polymer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3300510A (en) * | 1964-03-06 | 1967-01-24 | American Home Prod | Hydantoins |
| DE2714655A1 (en) * | 1977-04-01 | 1978-10-05 | Bayer Ag | METHOD OF MANUFACTURING HYDANTOIN |
| IL57504A0 (en) * | 1978-06-15 | 1979-10-31 | Beecham Group Ltd | Prostagandin analogues,their preparation and pharmaceutical compositions containing |
| DE4009506A1 (en) * | 1990-03-24 | 1991-09-26 | Hoechst Ag | hydantoin |
| US5100907A (en) * | 1990-05-02 | 1992-03-31 | Lonza, Inc. | Hydantoin esters |
| DE4126277A1 (en) * | 1991-08-08 | 1993-02-11 | Cassella Ag | HYDANTO DERIVATIVES |
-
1992
- 1992-04-24 DE DE4213634A patent/DE4213634A1/en not_active Withdrawn
-
1993
- 1993-04-03 EP EP93105575A patent/EP0566919B1/en not_active Expired - Lifetime
- 1993-04-03 ES ES93105575T patent/ES2194842T3/en not_active Expired - Lifetime
- 1993-04-03 AT AT93105575T patent/ATE236886T1/en not_active IP Right Cessation
- 1993-04-03 DE DE59310337T patent/DE59310337D1/en not_active Expired - Lifetime
- 1993-04-05 CZ CZ1993586A patent/CZ287885B6/en not_active IP Right Cessation
- 1993-04-12 US US08/045,994 patent/US5397796A/en not_active Expired - Lifetime
- 1993-04-23 CA CA002094773A patent/CA2094773C/en not_active Expired - Lifetime
- 1993-04-23 JP JP09809893A patent/JP3793242B2/en not_active Expired - Fee Related
- 1993-04-23 SK SK392-93A patent/SK39293A3/en unknown
- 1993-04-23 IL IL10551193A patent/IL105511A/en not_active IP Right Cessation
- 1993-04-28 AU AU38203/93A patent/AU665068B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US5397796A (en) | 1995-03-14 |
| ES2194842T3 (en) | 2003-12-01 |
| AU665068B2 (en) | 1995-12-14 |
| DE59310337D1 (en) | 2003-05-15 |
| EP0566919A1 (en) | 1993-10-27 |
| CZ58693A3 (en) | 1994-02-16 |
| DE4213634A1 (en) | 1993-10-28 |
| CZ287885B6 (en) | 2001-03-14 |
| SK39293A3 (en) | 1994-02-02 |
| IL105511A (en) | 1997-02-18 |
| CA2094773A1 (en) | 1993-10-25 |
| EP0566919B1 (en) | 2003-04-09 |
| AU3820393A (en) | 1993-10-28 |
| JPH06116245A (en) | 1994-04-26 |
| IL105511A0 (en) | 1993-08-18 |
| JP3793242B2 (en) | 2006-07-05 |
| ATE236886T1 (en) | 2003-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2094773C (en) | 2,4-dioxoimidazolidine derivatives | |
| US5554594A (en) | Imidazolidine derivatives | |
| CA2101179C (en) | Phenylimidazolidine derivatives, their preparation and their use | |
| CA2075590C (en) | Hydantoin derivatives | |
| US5658935A (en) | Heterocycles, their preparation and their use | |
| CA2130174C (en) | 4-oxo-2 thioxoimidazolidine derivatives as inhibitors of blood platelet aggregation | |
| US5981492A (en) | Substituted 5-membered ring heterocycles, their preparation and their use | |
| CA2155843C (en) | Novel urea derivatives, their preparation and use | |
| US5681838A (en) | Substituted amino compounds, their preparation and their use as inhibitors of thrombocyte-aggregation | |
| CA2154477C (en) | Substituted amino compounds, their preparation and their use as inhibitors of thrombocyte-aggregation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |